Core Viewpoint - The article discusses the ongoing legal claims against Derun Electronics (002055) due to false statements made by the company, which have led to significant financial discrepancies and potential investor compensation opportunities [1][2][3][4][5] Group 1: Legal Violations - Derun Electronics is under investigation by the Shenzhen Securities Regulatory Commission for alleged violations, including the fabrication of revenue figures amounting to CNY 394,584,426.91 in 2020 and CNY 112,960,100 in 2021 [3] - The company also understated credit impairment losses by CNY 371,151,433.40 and CNY 66,393,093.51 for the same years, and capital reserves were understated by CNY 321,316,487.76 and CNY 434,276,587.76 [3] - In June 2022, the company was found to have falsely recorded revenue of CNY 26,836,923.99 and understated credit impairment losses by CNY 5,060,996.46 due to financial maneuvers directed by the former chairman [2][3] Group 2: Impact on Financial Reports - The actions of Derun Electronics resulted in false disclosures in the annual reports for 2020 and 2021, as well as the semi-annual report for 2022 [4] - The company’s non-public offering report issued on January 11, 2022, also contained false information based on the previously mentioned financial data [4] Group 3: Investor Compensation - Investors who purchased Derun Electronics stock between August 27, 2020, and December 30, 2023, and either sold or continued to hold the stock after December 30, 2023, are eligible to file claims for compensation [5]

Core Viewpoint - The article discusses ongoing legal actions against Yitong Century (300310) due to false statements leading to investor claims, with a focus on recent court rulings and financial misconduct by the company [1][2]. Group 1: Legal Proceedings - Yitong Century is currently facing investor claims related to false statements, with lawsuits filed and ongoing efforts to accept additional claims from investors [1]. - A civil judgment was issued on December 30, 2025, requiring Yitong Century to compensate 109 investors a total of 2,729,003.27 yuan, with certain individuals held jointly liable for the company's debts [1]. - The law firm representing the investors has noted that previous claims have resulted in settlements, and they continue to pursue further cases [1]. Group 2: Financial Misconduct - An investigation revealed that from May 1 to December 31, 2017, Yitong Century's subsidiary, Beitai Health, engaged in financial fraud, inflating revenue by 97.34 million yuan, costs by 52.61 million yuan, and total profits by 40.84 million yuan, which constituted 3.7%, 9.75%, and 15.67% of the company's reported figures, respectively [2]. - This fraudulent activity led to the issuance of an administrative penalty by the China Securities Regulatory Commission on June 21, 2023, highlighting the company's failure to disclose accurate financial information in its annual reports [2]. Group 3: Investor Eligibility for Claims - Investors who purchased Yitong Century shares between April 3, 2018, and November 4, 2022, and sold or held their shares after November 4, 2022, are still eligible to file claims for compensation [3].

Core Viewpoint - New Yao Textile (002087) is facing administrative penalties from the China Securities Regulatory Commission (CSRC) due to false statements, leading to ongoing investor compensation claims [1][9]. Financial Misconduct - New Yao Textile inflated and deflated operating income, resulting in false records in annual reports from 2016 to 2022 [1][9]. - Specific methods of income inflation included: - False trades to inflate operating income [1][10]. - Repeatedly recognizing income to inflate operating income [2][10]. - Transactions between parent and subsidiary companies to inflate or deflate operating income [3][11]. - The company also inflated and deflated operating costs, leading to false records in annual reports from 2016 to 2022 [4][12]. - New Yao Textile inflated inventory, resulting in false records in annual reports from 2016 to 2022 [5][13]. - The company inflated research and development expenses, leading to false records in annual reports from 2016 to 2022 [6][14]. Financial Impact - In 2016, New Yao Textile inflated operating income by approximately 327.57 million yuan, reduced operating costs by about 176.57 million yuan, and inflated total profit by approximately 358.45 million yuan, which accounted for 159.81% of the disclosed profit [7][15]. - In 2017, the inflated operating income was approximately 415.19 million yuan, with a profit inflation of about 367.34 million yuan, accounting for 115.62% of the disclosed profit [7][15]. - In 2018, the inflated operating income was approximately 791.26 million yuan, with a profit inflation of about 284.35 million yuan, accounting for 65.78% of the disclosed profit [7][15]. - In 2019, the inflated operating income was approximately 1.21 billion yuan, with a profit inflation of about 582.74 million yuan, accounting for 180.47% of the disclosed profit [7][15]. - In 2020, the inflated operating income was approximately 1.03 billion yuan, with a profit inflation of about 390.94 million yuan, accounting for 199.63% of the disclosed profit [7][15]. - In 2021, the inflated operating income was approximately 666.64 million yuan, with a profit inflation of about 411.25 million yuan, accounting for 1,013.30% of the disclosed profit [7][15]. - In 2022, the inflated operating income was approximately 1.26 billion yuan, with a profit reduction of about 762.25 million yuan, accounting for 53.41% of the disclosed profit [7][15]. Legal Proceedings - Investors who purchased New Yao Textile shares between April 20, 2017, and April 27, 2023, and sold or held shares after April 27, 2023, are eligible to initiate compensation claims [8][16].

Core Viewpoint - The article discusses the ongoing legal actions and compensation claims against Yitong Century (宜通世纪) due to false statements that have led to investor losses, highlighting the potential for further claims by affected investors [1][3][4]. Group 1: Legal Proceedings - Yitong Century has been ordered by the Guangzhou Intermediate People's Court to compensate 109 investors a total of 2,729,003.27 yuan for investment losses, with a deadline of fifteen days from the judgment date for payment [4]. - The law firm Shanghai Jiucheng, represented by lawyer Xu Feng, is actively pursuing compensation claims for investors who purchased Yitong Century shares between April 3, 2018, and November 4, 2022, and either sold or continued to hold the shares after November 4, 2022 [3][5]. Group 2: Regulatory Actions - On June 21, 2023, Yitong Century received an administrative penalty decision from the China Securities Regulatory Commission (CSRC) due to violations related to financial misstatements during a major asset restructuring in October 2016 [2][4]. - The restructuring involved the acquisition of 100% of Shenzhen Beitai Health Measurement Analysis Technology Co., Ltd. for a total consideration of 1 billion yuan, which included issuing 21.7899 million shares and cash payment of 440 million yuan [2][4]. Group 3: Financial Misconduct - From May 1 to December 31, 2017, Beitai Health engaged in financial fraud, inflating revenue by 97.3439 million yuan, costs by 52.6099 million yuan, and total profit by 40.8386 million yuan, which represented 3.7%, 9.75%, and 15.67% of Yitong Century's reported figures, respectively [5].

Core Viewpoint - The article discusses the misleading statements made by Aolian Electronics regarding the achievements of Xu Mingjun in the perovskite industry, which have led to legal actions and investor claims for compensation [2][4][5]. Group 1: Misleading Statements - Aolian Electronics disclosed that Xu Mingjun's achievements in the perovskite field contained misleading statements, as he did not play a leading or key role in the 12 projects mentioned [2][3]. - The term "completion" used in the announcement only indicates Xu's participation in the projects, while "guidance" refers to suggestions he made, lacking significant technical or process contributions [3][4]. Group 2: Impact on Stock Performance - Following the announcement of the cooperation agreement on December 12, 2022, Aolian Electronics' stock price rose by 20.01%, while the ChiNext index fell by 0.79%, indicating a deviation of 20.80 percentage points [4][7]. - After the clarification statement from Huaneng Qingneng Institute on February 21, 2023, Aolian Electronics' stock price dropped by 29.92% over the next two days, while the ChiNext index only fell by 1.16%, showing a deviation of 28.76 percentage points [4][7]. Group 3: Legal Actions and Investor Claims - The Shanghai Jiucheng Law Firm, led by lawyer Xu Feng, is actively pursuing claims for investors who purchased Aolian Electronics' stock between December 12, 2022, and February 21, 2023, and are still holding or sold their shares after the clarification [5][7].

Core Viewpoint - The article discusses the legal actions taken against Ningke Biological (600165) for false statements in its financial reporting, highlighting the ongoing investor compensation efforts and the company's regulatory violations. Group 1: Legal Actions and Compensation - The Shanghai Jiucheng Law Firm, represented by lawyer Xu Feng, has submitted a new case for investor compensation related to Ningke Biological's false statements, with some investors already receiving compensation [1][5] - The law firm continues to accept claims from other investors affected by the company's actions [1][5] Group 2: Regulatory Violations - Ningke Biological's 2022 annual report contained false records, inflating revenue by 76.5941 million yuan and profit by 77.222 million yuan, which accounted for 11.25% and 46.59% of the total revenue and profit, respectively [5] - The company failed to timely disclose significant events, including major debts and the freezing of key bank accounts [2][6] - Additionally, the company did not disclose that a subsidiary's main business had come to a halt [3][5]

Core Viewpoint - Jiangsu Wuzhong (600200) is set to be delisted on December 31, 2025, due to ongoing legal issues related to false statements made by the company, prompting investors to seek compensation for their losses [1][4]. Group 1: Legal Proceedings - The law firm Shanghai Jiucheng has submitted a claim for investor compensation to the Suzhou Intermediate People's Court, with ongoing efforts to accept additional claims from affected investors [1][4]. - Investors who purchased Jiangsu Wuzhong shares between April 20, 2019, and February 27, 2025, and sold or continued to hold them after February 27, 2025, are eligible to initiate claims [6]. Group 2: Regulatory Violations - Jiangsu Wuzhong has been found guilty of failing to disclose its actual controller accurately, with false records in annual reports from 2018 to 2023 [4][5]. - The company inflated its operating revenue, costs, and profits from 2020 to 2023 through non-substantive trade activities with related companies, resulting in significant discrepancies in reported figures [2][5]. - The inflated operating revenues were reported as follows: 494.26 million yuan (26.46%), 468.51 million yuan (26.39%), 430.75 million yuan (21.26%), and 376.66 million yuan (16.82%) for the respective years [2][5]. - The inflated operating costs were reported as 480.68 million yuan (37.08%), 448.24 million yuan (35.47%), 410.82 million yuan (28.40%), and 355.44 million yuan (20.95%) [2][5]. - The inflated total profits were reported as 14.58 million yuan (2.89%), 20.27 million yuan (51.65%), 19.92 million yuan (26.42%), and 21.22 million yuan (29.81%) [2][5]. - There were also significant omissions regarding the disclosure of non-operating fund usage by related parties in annual reports from 2020 to 2023 [3][6].

许峰律师代理的长药控股投资者索赔案已向武汉市中级人民法院提交立案，目前正在等待法院的下一步 安排，律师团队同步还在继续推进后续案件的立案工作，还在继续接受其他投资者的索赔委托，长药控 股投资者索赔案已有投资者胜诉先例。 2025年12月26日，长药控股公告收到证监会下发的《行政处罚事先告知书》，根据《告知书》认定的事 实，公司2021年、2022年、2023年年度报告存在虚假记载，2021年至2023年年度报告分别虚增营业收入 21，532.38万元、28，373.66万元、23，363.46万元，占当期对外披露营业收入的9.12%、17.57%、 19.51%；虚增利润总额5，640.14万元、6，337.52万元、4，370.50万元，占当期对外披露利润总额绝对 值的35.62%、88.23%、6.42%。同时，由于2022年对长江伟创中药城交易中心工程项目未合理确认损 失，导致公司2022年年度报告虚增利润总额455.24万元，占当期对外披露利润总额的6.34%。公司可能 触及《深圳证券交易所创业板股票上市规则》第10.5.2条第（六）项的"根据中国证监会行政处罚决定载 明的事实，公司披露的年度报告财务 ...

Core Viewpoint - The article discusses ongoing legal actions for investor compensation against Nanjing Panda Electronics due to significant discrepancies between the company's profit forecasts and actual financial results, indicating potential false statements made by the company [1][2]. Group 1: Company Financial Discrepancies - Nanjing Panda announced an estimated net profit for 2023 of approximately 16.19 million to 24.29 million yuan, with a net profit excluding non-recurring gains and losses expected to be between -3.27 million and 4.82 million yuan [1]. - The actual net profit reported on March 29, 2024, was a loss of 237.86 million yuan, and the net profit excluding non-recurring gains and losses was a loss of 257.01 million yuan, showing a significant deviation from the earlier forecast [1]. Group 2: Legal Actions and Investor Rights - Investors who purchased Nanjing Panda stock between January 31, 2024, and March 29, 2024, and sold or continued to hold the stock after March 29, 2024, are eligible to initiate compensation claims [2]. - The law firm involved has a history of successfully representing investors in similar cases, having handled nearly 200 cases with favorable outcomes and currently managing around 300 ongoing claims [2].

Core Viewpoint - The article discusses the significant legal developments regarding investor claims against Puli Pharmaceutical (300630) due to false statements made by the company, leading to a court ruling in favor of investors [1][3]. Financial Misstatements - Puli Pharmaceutical falsely reported sales revenue and profits by fabricating sales of finished and raw pharmaceutical products from 2021 to 2022. In 2021, the company overstated revenue by 436,606,838.34 yuan, which accounted for 28.94% of the reported revenue, and overstated profits by 308,018,435.49 yuan, representing 65.88% of the total reported profit [4][5]. - In 2022, the company overstated revenue by 456,639,341.72 yuan, which was 25.28% of the reported revenue, and overstated profits by 387,417,257.52 yuan, making up 88.27% of the total reported profit [4][5]. Additional Revenue Miscalculations - The company also miscalculated revenue from non-controlling trade activities, leading to an additional overstatement of 77,997,346.38 yuan in 2021 (5.17% of reported revenue) and 59,259,735.84 yuan in 2022 (3.28% of reported revenue) [2][6]. Legal Proceedings - The law firm Shanghai Jiucheng, led by attorney Xu Feng, is actively pursuing further claims and has already achieved a favorable ruling for investors in a recent case. Investors who purchased Puli Pharmaceutical shares between April 26, 2022, and April 17, 2024, are eligible to file claims [3][6].